ALFACELL CORP
SC 13D/A, 2000-02-29
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: PRIME CASH FUND, N-30D, 2000-02-29
Next: SELIGMAN COMMUNICATIONS & INFORMATION FUND INC, NSAR-B, 2000-02-29




                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  Schedule 13D

                    Under the Securities Exchange Act of 1934
                               (Amendment No. 2)*

                              Alfacell Corporation
                                (Name of Issuer)

                            Common Stock and Options
                          (Title of Class of Securities

                                    015404106
                                 (CUSIP Number)

                                 Kuslima Shogen
                              Alfacell Corporation
                              225 Belleville Avenue
                              Bloomfield, NJ 01003
                                  (973)748-8082
                  (Name, Address and Telephone Number of Person
                Authorized to Receive Notices and Communications)

                               September 30, 1999
             (Date of Event which Requires Filing of this Statement)

If the filing person has previously  filed a statement on Schedule 13G to report
the  acquisition  which is the subject of this  Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box. [__]

     Note: Six copies of this statement, including all exhibits, should be filed
     with the Commission. See Rule 13d-1(a) for other parties to whom copies are
     to be sent.

* The remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for any  subsequent  amendment  containing  information  which  would  alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 ("Act") or otherwise  subject to the liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).


<PAGE>



CUSIP No. 015404106                 13D                        Page 2 of 6 pages



- --------------------------------------------------------------------------------
   1   NAME OF REPORTING PERSON
       S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

       Kuslima Shogen

- --------------------------------------------------------------------------------
   2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                             (a)  [  ]
                                                             (b)  [  ]


- --------------------------------------------------------------------------------
   3   SEC USE ONLY




- --------------------------------------------------------------------------------
   4   SOURCE OF FUNDS


       SC

- --------------------------------------------------------------------------------
   5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
       ITEMS 2(D) OR 2(E)                                         [X]


- --------------------------------------------------------------------------------
   6   CITIZENSHIP OR PLACE OF ORGANIZATION


       United States

- --------------------------------------------------------------------------------
   NUMBER OF      7    SOLE VOTING POWER
     SHARES            2,680,585  (includes 1,431,965 shares subject to options
  BENEFICIALLY         which are  currently  exercisable  or which will  become
    OWNED BY           exercisable within 60 days of September 30, 1999).
      EACH        --------------------------------------------------------------
   REPORTING      8    SHARED VOTING POWER
     PERSON            0
      WITH        --------------------------------------------------------------
                  9    SOLE DISPOSITIVE POWER
                       2,680,585 (includes 1,431,965 shares subject to options
                       which are currently exercisable or which will will
                       become exercisable within 60 days of September 30,
                       1999).
                  --------------------------------------------------------------
                  10   SHARED DISPOSITIVE POWER
                       0

- --------------------------------------------------------------------------------
  11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       2,680,585 (includes 1,431,965 shares subject to options
       which are currently exercisable or which will become
       exercisable within 60 days of September 30, 1999).
- --------------------------------------------------------------------------------
  12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

                                                                       [  ]

- --------------------------------------------------------------------------------
  13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

       14.3%

- --------------------------------------------------------------------------------
  14   TYPE OF REPORTING PERSON*

       IN


- --------------------------------------------------------------------------------
                     *SEE INSTRUCTIONS BEFORE FILLING OUT!



<PAGE>

                                                               Page 3 of 5 pages

Item 1. Security and Issuer


     The securities to which this Schedule 13D relates are the shares of common
stock, par value $.001 per share (the "Common Stock"), of Alfacell Corporation
(the "Issuer"). The address of the Issuer's principal executive offices is 225
Belleville Avenue, Bloomfield, NJ 07003

Item 2. Identity and Background

     (a) - (c) The person (the "Reporting Person") filing this statement is
Kuslima Shogen, Chief Executive Officer and Chairman of the Board of the Issuer.
The Reporting Person's mailing address is c/o Alfacell Corporation, 225
Belleville Avenue, Bloomfield, NJ 07003.

     (d) During the last five years, the Reporting Person has not been convicted
in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     (e) The Reporting Person entered a consent decree with the Securities and
Exchange Commission ("SEC") on March 4, 1998 pursuant to which she was fined
$20,000 for alleged violations of Sections 13 and 16(a) of the Securities
Exchange Act of 1934, as amended. In connection with the settlement, the
Reporting Person neither admitted nor denied the allegations of the SEC and
agreed not to violate Sections 13 and 16(a) in the future.

     (f) The Reporting Person is a citizen of the United States.

Item 3. Source and Amount of Funds or Other Consideration

     The Reporting Person received the grants of stock and/or options to
purchase Common Stock from the Company pursuant to certain employee benefit
transactions. In addition, the Reporting Person personally borrowed funds from
financial institutions to finance the Issuer's operations, for which she
received securities of the Issuer in exchange.

Item 4. Purpose of the Transaction

     The Common Stock and options to purchase Common Stock were acquired by the
Reporting Person as the founder and subsequently as an employee of the Issuer.

Item 5. Interest in Securities of the Issuer

     (a) The Reporting Person beneficially owns 2,680,585 shares of Common
Stock, consisting of 1,248,620 shares of Common Stock currently issued and
1,431,965 shares underlying options to purchase Common Stock held by the


<PAGE>


                                                               Page 4 of 5 pages

Reporting Person.  Such shares constitute 14.3% of the Common Stock
outstanding assuming all of the options are exercised.

     (b) The Reporting Person has the sole power to vote or to direct the vote
and the sole power to dispose or direct the disposition of the shares of Common
Stock.

     (c) None.

     (d) The Reporting Person has pledged a total of 1,023,000 of the
outstanding shares of Common Stock to First Union National Bank (the "Bank") to
secure a personal loan. Upon the sale of the shares of Common Stock held by the
Reporting Person, the Bank has the right to apply such proceeds thereof to such
loan.

     (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
        Securities of the Issuer

     Not Applicable

Item 7. Material to be Filed as Exhibits

     Not Applicable



<PAGE>


                                                               Page 5 of 5 pages

Signature

     After reasonable inquiry and to the best of the knowledge and belief of
each of the undersigned, the undersigned certifies that the information set
forth in this statement by or about the undersigned is true, complete and
correct.


Date: February 28, 2000

                                                 By: /s/ Kuslima Shogen
                                                    ----------------------
                                                     Kuslima Shogen



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission